What question did this study set out to answer?

This study aims to evaluate the safety and effectiveness of glipizide for treating diabetes associated with pancreatic cancer.

June 7, 2026Diabetes

1813-P: Effect of Glipizide on Weight and Glycemic Control in Pancreatic Cancer–Associated Diabetes: A Prospective Clinical Trial

View Full Paper

Ask AI

Bookmark

This study aims to evaluate the safety and effectiveness of glipizide for treating diabetes associated with pancreatic cancer.
Single-arm, prospective trial of extended-release glipizide in adults with PDAC-DM (N=20)
Primary endpoints: change in mean CGM glucose and symptomatic hypoglycemia
Secondary endpoints included quality of life, metabolic biomarkers, and body composition measurements.
Glipizide reduced CGM-derived glucose by 40 mg/dL (p=0.019)
HbA1c decreased by 1.5% (p=0.004)
HOMA-B increased from 22 to 56 (p=0.042) with improved quality of life over 4 months.

No takes yet. Share an insight, caveat, or question.

Prospective trial shows that glipizide improves glycemic control in patients with pancreatic cancer-related diabetes, suggesting clinical benefits.

Ryan et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Prospective trial shows that glipizide improves glycemic control in patients with pancreatic cancer-related diabetes, suggesting clinical benefits.